Avidity Partners Management LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Avidity Partners Management LP reported 63 stock positions worth $484.9 million. Its top holding was Boston Scientific (BSX) at 7.0% of the portfolio, followed by Dianthus Therapeutics (DNTH, 6.4%) and Unitedhealth (UNH, 5.5%). Compared with Q4 2024, it opened 19 new positions, sold out of 17, added to 3 and reduced 36. The biggest buy was a new position in Beam Therapeutics (BEAM) and the biggest sale an exit from Intuitive Surgical (ISRG).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0001791827
- Portfolio Value
- $484.9M (Q1 2025)
- SEC Filing
- 0001791827-25-000005 ↗ filed May 15, 2025
Holdings Value
Holdings 63 stocks · $484.9M
| BSX Boston Scientific Corp. | 6.99% | 336,000 | $33.9M | Reduce -34.8% |
| DNTH Dianthus Therapeutics Inc. | 6.44% | 1,720,902 | $31.2M | Reduce -40.1% |
| UNH Unitedhealth Group Inc. | 5.46% | 50,500 | $26.4M | Reduce -15.8% |
| CGON CG Oncology Inc. | 4.95% | 980,942 | $24.0M | Reduce -10.6% |
| HUM Humana Inc. | 4.42% | 81,000 | $21.4M | Reduce -9.2% |
| NTRA Natera Inc. | 3.48% | 119,200 | $16.9M | Reduce -46.7% |
| REGN Regeneron Pharmaceuticals | 3.32% | 25,400 | $16.1M | Add +202.4% |
| EXAS Exact Sciences Corp. | 3.15% | 353,000 | $15.3M | Reduce -41.5% |
| BEAM Beam Therapeutics Inc. | 2.86% | 709,517 | $13.9M | New |
| GKOS Glaukos Corp. | 2.72% | 134,000 | $13.2M | Reduce -21.2% |
| DXCM Dexcom Inc. | 2.54% | 180,000 | $12.3M | Reduce -43.4% |
| RARE Ultragenyx Pharmaceutical Inc. | 2.41% | 322,100 | $11.7M | Reduce -8.5% |
| SNDX Syndax Pharmaceuticals Inc. | 2.34% | 925,000 | $11.4M | Reduce -38.3% |
| COR Cencora Inc. | 2.25% | 39,300 | $10.9M | New |
| JAZZ Jazz Pharmaceuticals PLC | 2.05% | 80,000 | $9.9M | Reduce -65.9% |
| THC Tenet Healthcare Corp. | 2.00% | 72,000 | $9.7M | Reduce -47.5% |
| NBIX Neurocrine Biosciences Inc. | 1.95% | 85,700 | $9.5M | Reduce -61.1% |
| DHR Danaher Corp. | 1.88% | 44,500 | $9.1M | Reduce -33.6% |
| AXSM Axsome Therapeutics Inc. | 1.85% | 77,000 | $9.0M | Reduce -59.0% |
| INSM Insmed Inc. | 1.68% | 107,000 | $8.2M | Reduce -54.0% |
| OGN Organon & Co. | 1.64% | 535,000 | $8.0M | New |
| TMO Thermo Fisher Scientific Inc. | 1.59% | 15,500 | $7.7M | Reduce -65.3% |
| XENE Xenon Pharmaceuticals Inc. | 1.58% | 229,000 | $7.7M | Reduce -51.7% |
| XBI SS SPDR S&P Biotech ETF | 1.57% | 94,000 | $7.6M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.57% | 529,000 | $7.6M | Reduce -54.6% |
| RVMD Revolution Medicines Inc. | 1.55% | 213,000 | $7.5M | Reduce -52.3% |
| TEVA Teva Pharmaceutical-SP ADR | 1.52% | 481,000 | $7.4M | New |
| AVTR Avantor Inc. | 1.51% | 453,000 | $7.3M | Reduce -52.2% |
| IDYA Ideaya Biosciences Inc. | 1.50% | 445,000 | $7.3M | Reduce -60.5% |
| DOCS Doximity Inc. Class A | 1.47% | 122,500 | $7.1M | New |
| JANX Janux Therapeutics Inc. | 1.44% | 258,000 | $7.0M | Reduce -65.2% |
| HQY Healthequity Inc. | 1.42% | 78,000 | $6.9M | New |
| BPMC Blueprint Medicines Corp. | 1.25% | 68,500 | $6.1M | Reduce -61.2% |
| UTHR United Therapeutics Corp. | 1.07% | 16,800 | $5.2M | New |
| PHAT Phathom Pharmaceuticals Inc. | 1.03% | 800,000 | $5.0M | Reduce -42.5% |
| IMUX Immunic Inc. | 1.00% | 4,454,408 | $4.9M | Reduce -44.1% |
| BRKR Bruker Corp. | 0.99% | 115,000 | $4.8M | Add +50.7% |
| CATX Perspective Therapeutics Inc. | 0.97% | 2,197,270 | $4.7M | Reduce -18.5% |
| CNTX Context Therapeutics Inc. | 0.94% | 7,477,200 | $4.6M | No change |
| ORKA Oruka Therapeutics Inc. | 0.75% | 352,124 | $3.6M | No change |
| QURE Uniqure NV | 0.73% | 336,200 | $3.6M | Add +51.4% |
| BHVN Biohaven Ltd. | 0.72% | 145,000 | $3.5M | Reduce -35.0% |
| ARVN Arvinas Inc. | 0.60% | 413,162 | $2.9M | Reduce -69.6% |
| ACAD Acadia Pharmaceuticals Inc. | 0.58% | 169,000 | $2.8M | New |
| RPRX Royalty Pharma PLC Class A | 0.56% | 87,000 | $2.7M | New |
| BBIO Bridgebio Pharma Inc. | 0.53% | 75,000 | $2.6M | New |
| KZR Kezar Life Sciences Inc. | 0.51% | 502,600 | $2.5M | No change |
| AKRO Akero Therapeutics Inc. | 0.48% | 57,000 | $2.3M | Reduce -30.5% |
| SLNO Soleno Therapeutics Inc. | 0.47% | 32,000 | $2.3M | New |
| CAPR Capricor Therapeutics Inc. | 0.47% | 239,000 | $2.3M | New |
| LXEO Lexeo Therapeutics Inc. | 0.46% | 645,000 | $2.2M | New |
| VERA Vera Therapeutics Inc. | 0.45% | 91,000 | $2.2M | Reduce -9.0% |
| RGNX Regenxbio Inc. | 0.38% | 260,000 | $1.9M | Reduce -51.1% |
| IONS Ionis Pharmaceuticals Inc. | 0.37% | 60,000 | $1.8M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.37% | 40,000 | $1.8M | Reduce -94.0% |
| NAMS Newamsterdam Pharma Co. NV | 0.29% | 68,000 | $1.4M | Reduce -80.8% |
| AGL Agilon Health Inc. | 0.27% | 305,100 | $1.3M | New |
| SCYX Scynexis Inc. | 0.24% | 1,228,910 | $1.2M | No change |
| PCVX Vaxcyte Inc. | 0.18% | 23,000 | $868K | New |
| KPTI Karyopharm Therapeutics Inc. | 0.10% | 134,566 | $503K | No change |
| ELVN Enliven Therapeutics Inc. | 0.05% | 11,300 | $222K | New |
| HYPR Hyperfine Inc. | 0.03% | 222,174 | $159K | Reduce -81.3% |
| REVIVA PHARMACEUTCLS HLDGS I | 0.03% | 138,000 | $132K | New |
Options reported separately and not counted above: HUM calls ($21.2M), GMAB calls ($8.5M), ARVN calls ($5.3M), SNDX calls ($4.9M).
Portfolio Sells Q4 2024 → Q1 2025
| ISRG Intuitive Surgical Inc. | Sold out | 0.00% | −3.37 |
| ACHC Acadia Healthcare Co. Inc. | Sold out | 0.00% | −2.60 |
| JANX Janux Therapeutics Inc. | Reduce -65.2% | 1.44% | −2.52 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -94.0% | 0.37% | −2.37 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −2.01 |
| ARVN Arvinas Inc. | Reduce -69.6% | 0.60% | −2.00 |
| ILMN Illumina Inc. | Sold out | 0.00% | −1.46 |
| ABBV Abbvie Inc. | Sold out | 0.00% | −1.43 |
| IDYA Ideaya Biosciences Inc. | Reduce -60.5% | 1.50% | −1.38 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −1.32 |
| BMY Bristol-Myers Squibb Co. | Sold out | 0.00% | −1.21 |
| TMDX Transmedics Group Inc. | Sold out | 0.00% | −1.20 |
| SGRY Surgery Partners Inc. | Sold out | 0.00% | −1.09 |
| NBIX Neurocrine Biosciences Inc. | Reduce -61.1% | 1.95% | −1.04 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −1.02 |
| INCY Incyte Corp. | Sold out | 0.00% | −0.89 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −0.85 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -65.9% | 2.05% | −0.83 |
| ITCI Intra-Cellular Therapies Inc. | Sold out | 0.00% | −0.81 |
| TMO Thermo Fisher Scientific Inc. | Reduce -65.3% | 1.59% | −0.72 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -80.8% | 0.29% | −0.62 |
| AVTR Avantor Inc. | Reduce -52.2% | 1.51% | −0.47 |
| RVMD Revolution Medicines Inc. | Reduce -52.3% | 1.55% | −0.39 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -54.6% | 1.57% | −0.38 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −0.33 |
| BPMC Blueprint Medicines Corp. | Reduce -61.2% | 1.25% | −0.28 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -51.7% | 1.58% | −0.27 |
| EXAS Exact Sciences Corp. | Reduce -41.5% | 3.15% | −0.23 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.23 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −0.22 |
| BHVN Biohaven Ltd. | Reduce -35.0% | 0.72% | −0.11 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -42.5% | 1.03% | −0.09 |
| HYPR Hyperfine Inc. | Reduce -81.3% | 0.03% | −0.07 |
| BLUEBIRD BIO INC | Sold out | 0.00% | −0.07 |
| NTRA Natera Inc. | Reduce -46.7% | 3.48% | −0.06 |
| RGNX Regenxbio Inc. | Reduce -51.1% | 0.38% | −0.03 |
| VERA Vera Therapeutics Inc. | Reduce -9.0% | 0.45% | +0.03 |
| DXCM Dexcom Inc. | Reduce -43.4% | 2.54% | +0.07 |
| INSM Insmed Inc. | Reduce -54.0% | 1.68% | +0.08 |
| CATX Perspective Therapeutics Inc. | Reduce -18.5% | 0.97% | +0.11 |
| GKOS Glaukos Corp. | Reduce -21.2% | 2.72% | +0.18 |
| DNTH Dianthus Therapeutics Inc. | Reduce -40.1% | 6.44% | +0.20 |
| IMUX Immunic Inc. | Reduce -44.1% | 1.00% | +0.21 |
| AKRO Akero Therapeutics Inc. | Reduce -30.5% | 0.48% | +0.25 |
| AXSM Axsome Therapeutics Inc. | Reduce -59.0% | 1.85% | +0.27 |
| THC Tenet Healthcare Corp. | Reduce -47.5% | 2.00% | +0.27 |
| DHR Danaher Corp. | Reduce -33.6% | 1.88% | +0.35 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -38.3% | 2.34% | +0.37 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -8.5% | 2.41% | +0.93 |
| CGON CG Oncology Inc. | Reduce -10.6% | 4.95% | +1.82 |
Portfolio Buys Q4 2024 → Q1 2025
| BEAM Beam Therapeutics Inc. | New | 2.86% | +2.86 |
| REGN Regeneron Pharmaceuticals | Add +202.4% | 3.32% | +2.73 |
| COR Cencora Inc. | New | 2.25% | +2.25 |
| OGN Organon & Co. | New | 1.64% | +1.64 |
| XBI SS SPDR S&P Biotech ETF | New | 1.57% | +1.57 |
| TEVA Teva Pharmaceutical-SP ADR | New | 1.52% | +1.52 |
| DOCS Doximity Inc. Class A | New | 1.47% | +1.47 |
| HQY Healthequity Inc. | New | 1.42% | +1.42 |
| UTHR United Therapeutics Corp. | New | 1.07% | +1.07 |
| ACAD Acadia Pharmaceuticals Inc. | New | 0.58% | +0.58 |
| RPRX Royalty Pharma PLC Class A | New | 0.56% | +0.56 |
| BRKR Bruker Corp. | Add +50.7% | 0.99% | +0.54 |
| BBIO Bridgebio Pharma Inc. | New | 0.53% | +0.53 |
| SLNO Soleno Therapeutics Inc. | New | 0.47% | +0.47 |
| CAPR Capricor Therapeutics Inc. | New | 0.47% | +0.47 |
| LXEO Lexeo Therapeutics Inc. | New | 0.46% | +0.46 |
| IONS Ionis Pharmaceuticals Inc. | New | 0.37% | +0.37 |
| QURE Uniqure NV | Add +51.4% | 0.73% | +0.34 |
| AGL Agilon Health Inc. | New | 0.27% | +0.27 |
| PCVX Vaxcyte Inc. | New | 0.18% | +0.18 |
| ELVN Enliven Therapeutics Inc. | New | 0.05% | +0.05 |
| REVIVA PHARMACEUTCLS HLDGS I | New | 0.03% | +0.03 |
Options Activity Q4 2024 → Q1 2025
| HUM Humana Inc. | call | New | 80,000 | $21.2M |
| GMAB Genmab A/S -SP ADR | call | New | 433,100 | $8.5M |
| ARVN Arvinas Inc. | call | Add +7.1% | 750,000 | $5.3M |
| SNDX Syndax Pharmaceuticals Inc. | call | New | 400,000 | $4.9M |
| NMRA Neumora Therapeutics Inc. | call | Sold out | 150,000 | $1.6Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 45 | $624.4M | DNTH, CGON, ORKA, JBIO, ELVN |
| Q1 2026Amended | 45 | $493.8M | DNTH, CGON, ORKA, CATX, JBIO |
| Q4 2025 | 39 | $346.7M | DNTH, CGON, JBIO, ORKA, TEVA |
| Q3 2025 | 43 | $439.4M | DNTH, CGON, MDT, BSX, ORKA |
| Q2 2025 | 55 | $498.8M | CGON, BSX, NTRA, DNTH, EXAS |
| Q1 2025 | 63 | $484.9M | BSX, DNTH, UNH, CGON, HUM |
| Q4 2024 | 61 | $1.0B | DNTH, BSX, JANX, NTRA, EXAS |
| Q3 2024 | 81 | $2.0B | BSX, DNTH, ISRG, NTRA, CGON |
| Q2 2024 | 84 | $2.4B | ISRG, BSX, NTRA, ARVN, ACHC |
| Q1 2024 | 86 | $2.8B | FUSN, BSX, ARVN, ISRG, DNTH |